-transparent.png){kind=logo}
Antilymphocyte sera (ALS) were prepared by different methods and examined for their myelotoxicity by bone marrow colony-forming assay, both before and after absorption with B cell antigens. The results show that myelotoxicity can readily be removed from some, but not all, ALS. The source of antigen and the immunisation protocol used determine the degree of myelotoxicity and hence the number of absorptions required. Non-myelotoxic ALS may be suitable for the prevention of graft-versus-host disease (GVHD) by in vitro treatment of bone marrow before transplantation.
Related Publications
M Y Gordon, and
H Zola
October 1968,
Biulleten' eksperimental'noi biologii i meditsiny,
M Y Gordon, and
H Zola
June 1970,
Lymphology,
M Y Gordon, and
H Zola
March 1979,
Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M Y Gordon, and
H Zola
March 1971,
Transplantation proceedings,
M Y Gordon, and
H Zola
June 1970,
American journal of clinical pathology,
M Y Gordon, and
H Zola
January 1968,
Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimentelle Chirurgie,
M Y Gordon, and
H Zola
January 1972,
Folia biologica,
M Y Gordon, and
H Zola
March 1967,
Deutsche medizinische Wochenschrift (1946),
M Y Gordon, and
H Zola
September 1969,
The Journal of infectious diseases,
M Y Gordon, and
H Zola
June 1971,
Clinical and experimental immunology,
